VIR: SEC Form 4 filed by Vir Biotechnology Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for VIR
Across the 27 sessions after earlier VIR headlines, the stock closed higher 12 times and lower 15 times, with a median move of 2.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VIR | SPY |
|---|---|---|---|
| Oct 28, 2026 | Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors | +3.1% | +0.3% |
| Oct 22, 2026 | Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results | -1.3% | -1.2% |
| Oct 14, 2026 | Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors | -1.9% | -1.1% |
| Oct 8, 2026 | Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer | -3.5% | -0.4% |
| Oct 7, 2026 | Vir Biotechnology Appoints David Liu as Chief Medical Officer | -0.7% | -0.2% |
| Oct 6, 2026 | Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026 | -1.5% | +0.5% |
Earlier insider filings at VIR
- Aug 12, 2026Director More Robert J disposed of 8,000 shares and acquired 8,000 shares, decreasing direct ownership by 16% to 40,656 units (SEC Form 4)
- Jun 10, 2026Director Coughlin Timothy was granted 16,000 units of Common Stock (SEC Form 4)
- Jun 2, 2026Director Napolitano Janet sold $30,240 worth of shares (3,200 units at $9.45) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 21,216 units (SEC Form 4)
- Jun 2, 2026SVP, Chief Accounting Officer Sabatini Brent sold $3,582 worth of Common Stock (379 units at $9.45) as part of a pre-agreed trading plan, decreasing direct ownership by 0.61% to 61,902 units (SEC Form 4)
- May 28, 2026Director Sigal Charles Elliott was granted 8,000 shares, increasing direct ownership by 25% to 39,806 units (SEC Form 4)
Keep researching VIR
- VIR insider tradesEvery buy and sale reported by Vir Biotechnology Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- VIR earnings historyPast Vir Biotechnology Inc. earnings releases, newest first.
- VIR financial statementsRevenue, profit, cash flow and balance sheet from Vir Biotechnology Inc.'s SEC filings.
Quantisnow market dataNASDAQ
VIR
Vir Biotechnology Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2019
Get push alerts for VIR
Full VIR profile on Quantisnow Follow VIR and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time